Grégory Ehx, en collaboration avec plusieurs équipes canadiennes, a créé ce programme informatique, rendu libre d'accès, permettant de découvrir des cibles de choix pour créer des vaccins anti-cancer.
Among the grants awarded by the FRS-FNRS this year, 118 will finance research carried out by ULiège scientists.
Michaëls Herfs has been awarded this prize for his original and daring research project focused on cervical cancer.
In the latest issue of Cell, Julie Stoufflet, Sylvia Tielens and Laurent Nguyen publish a review summarizing the latest discoveries concerning the cellular dialogues that shape the cerebral cortex.
Congratulations to Arnaud Blomme, Grégory Ehx and Stéphanie Herkenne for their FNRS Research Associate mandate ! We wish them the best with their GIGA projects.
The new annual report is on line. You'll find a review of the previous year's research activities, a selection of the best publications and an interview with Liesbet Geris, after she was awarded her 3rd ERC.
A multidisciplinary research team led by ULiège and CHU Liège has uncovered evidence of increased neuronal connectivity in the brains of entrepreneurs, which may contribute to distinct cognitive attributes.
The laboratories of Luc Willems (GIGA-Cancer) and Vincent Seutin (GIGA-Neurosciences) have just published a study which establishes the scientific basis of a new therapeutic strategy for Steinert’s disease.
After discovering in 2019 that the drug had antbacterial properties, the team of Profs Cécile Oury and Patrizio Lancellotti is publishing this time a study on its effect on infective endocarditis.
Pierre Close (Cancer Signaling Laboratory - GIGA Stem Cells) has been selected for his project "Demystifying what makes melanoma so good at resisting treatments" and is receiving £155,000 in funding.
Sophie obtained a "young researcher" funding of 60.000€ for her project on the effect of alcohol on the brain of adolescents and Pierre a credit of 120.000€ for his projects on the use of the 7 Tesla MRI in neurological research.
This study by Akeila Bellahcène's team (Metastasis Research Laboratory) characterized an epigenomic signature of methylglyoxal that effectively discriminates triple-negative breast cancer patients with poor survival.
